This is a routine administrative filing with no trading implications. The original 10-K financials and disclosures remain unchanged. Monitor the proxy statement when filed, as it will contain the same Part III information incorporated by reference.
Price Chart
Executive Summary
Autonomix Medical filed Amendment No. 1 to its 10-K for the fiscal year ended March 31, 2026, exclusively to add the Part III information (Items 10-14: directors, executive compensation, security ownership, related transactions, and principal accounting fees) that was omitted from the original filing. This is a purely administrative amendment — no financial statements were restated, no changes were made to the original 10-K financials, and the original 10-K filing date of May 27, 2026 remains unaffected. The amendment carries no new financial or operational disclosures and has no market impact.
Key Facts
- Amendment No. 1 to Form 10-K/A filed solely to include Items 10-14 (Part III) originally omitted per General Instruction G(3) pending a definitive proxy statement.
- No financial statements were included or amended; no restatements, error corrections, or going-concern items were disclosed.
- New Section 302 certifications (Exhibits 31.3 and 31.4) were filed; Section 906 certifications were not required due to no financial statements in the amendment.
- Principal accounting fees for FY2026 were $506,530 (audit: $490,205, tax: $16,325), down from $566,496 in FY2025.
- As of March 31, 2026, all named executive officers and non-employee directors held zero outstanding stock options.
- Aggregate beneficial ownership of all executive officers and directors was 3.2% of outstanding shares (363,024 shares) as of June 1, 2026.
Financial Impact
No financial impact — the amendment contains no new financial data, restatements, or guidance changes.
Risk Factors
- No new risks disclosed; the amendment is purely procedural.
- The company continues as an early-stage medical device developer with a $4M market cap and no revenue from operations — this filing does not alter that risk profile.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001437749-26-020686 |
| Exhibit: ex_967098.htm | 0001437749-26-020686 |
| Exhibit: ex_967099.htm | 0001437749-26-020686 |
| Document: 0001437749-26-020686-index-headers.html | 0001437749-26-020686 |
| Document: 0001437749-26-020686-index.html | 0001437749-26-020686 |
| Document: 0001437749-26-020686.txt | 0001437749-26-020686 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 3 | $3.01 | awaiting T+20 | — | $2.11 (−29.90%) |
Oct 2, 2026 25d ago | Press Release | $3.78 | awaiting T+20 | — | $2.11 (−44.18%) |
Sep 16, 2026 5w ago | 8-K | $4.12 $3.01 | ▼ −26.94% | ▼ −30.12% | $2.11 (−48.79%) |
Sep 16, 2026 5w ago | EFFECT | $4.12 $3.01 | ▲ +26.94% | ▲ +30.12% | $2.11 (+48.79%) |
Sep 11, 2026 6w ago | 424B5 | $4.33 $3.10 | ▲ +28.41% | ▲ +30.67% | $2.11 (+51.27%) |
Sep 4, 2026 7w ago | S-3 | $4.58 $3.47 | ▲ +24.24% | ▲ +25.95% | $2.11 (+53.93%) |
Aug 26, 2026 8w ago | 8-K | $5.63 $4.07 | ▼ −27.71% | ▼ −27.20% | $2.11 (−62.52%) |
Aug 5, 2026 11w ago | EFFECT | $12.10 $4.50 | ▼ −62.81% | ▼ −62.21% | $2.11 (−82.56%) |
Jul 28, 2026 12w ago | 8-K | $2.75 $7.19 | ▲ +161.45% | ▲ +158.07% | $2.11 (−23.27%) |
Jul 15, 2026 14w ago | 8-K | $4.92 $6.86 | ▼ −39.43% | ▼ −35.81% | $2.11 (+57.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers